FLT3 and acute myeloid leukemia: For the ND AML cohort, CR/CRi rates were not significantly different not only between FLT3mut and FLT3wt groups (79.3% vs. 61.2%, p = 0.072) but also between FLT3‐ITD and FLT3wt groups (80.0% vs. 61.2%, p = 0.079), respectively.